Clifford Chance
Peter A. Laveran-Stiebar is a Corporate M&A partner currently based in New York after spending more than twelve years based in London.
Peter’s transactional practice focuses on cross-border acquisitions and divestitures for companies headquartered outside the United States, particularly in the life sciences sector. Peter has deep experience leading multi-jurisdictional and multi-practice teams supporting non-US corporate clients on complex investments in the United States and globally.
Peter also has experience advising US and global life sciences companies in post-merger integration matters, leading post-merger integration efforts in more than 75 jurisdictions worldwide.
- Represented Novo Nordisk A/S on a number of M&A matters including in its agreement to acquire ocedurenone for uncontrolled hypertension with potential application in cardiovascular and kidney disease from KBP Biosciences for up to US$1.3 billion.
- Represented Stabilus SE on its US$680 million acquisition of U.S. automation specialist DESTACO.
- Represented Bayer AG in the sale of the Coppertone sun care business to Beiersdorf AG for US$550 million and the Dr. Scholl's foot care business to Yellow Wood Partners for US$585 million.
- Represented Stagecoach Group PLC in its US$271 million sale of Coach USA to Variant Equity.
- Represented GlaxoSmithKline LLC on its collaboration with, and US$300 million investment in, 23andMe and the sale of an antibody (raxibacumab) for the treatment of inhalational anthrax to Emergent BioSolutions Inc.
- Represented Eisai Co., Ltd. and Eisai Inc. on the acquisition of all global development and marketing rights for the chronic weight management treatment lorcaserin hydrochloride (BELVIQ) from Arena Pharmaceuticals, Inc.
- Represented Pharming Group N. V. on the acquisition of all North American commercialization rights to Ruconest® from Valeant for an upfront fee of U.S. US$60 million and potential sales milestones payments totaling a maximum of U.S. US$65 million.
- Represented European telecommunications company Altice S.A. in a US$9.1 billion transaction to acquire a controlling stake in Suddenlink, the seventh largest cable operator in the U.S.
- Represented Indivior plc, formerly RB Pharmaceuticals, in its demerger from Reckitt Benckiser and £1 billion listing on the London Main Market.
- Represented Meda AB on numerous acquisitions including its acquisition of Acton Pharmaceuticals, a portfolio of pharmaceutical products from Jazz Pharmaceuticals, and MidNite, an OTC sleep aid product.
- Represented Magticom Ltd., the leading mobile operator in the Republic of Georgia, in its acquisition of retail and corporate ISP cable assets from Caucasus Online LLC and its acquisition of Deltacom Ltd., a Georgian retail internet services provider.
- Represented Altice in the US$1 billion co-investment by funds advised by BC Partners and Canada Pension Plan Investment Board in Cablevision Systems Corporation.
- Represented ITOCHU Corporation and ITOCHU International Inc. in the sale of PrimeSource Building Products, Inc., a North American distributor of building materials, to Platinum Equity.
- Represented Correvio LLC, a Switzerland-based pharmaceutical company, in its sale to Cardiome Pharma Corp., a Toronto Stock Exchange and NASDAQ listed company, in return for 17% of the outstanding Cardiome common shares post-transaction and deferred cash payments.
- Represented funds managed by HealthpointCapital, LLC in the sale of their controlling interest in Scient'x Groupe SAS to Alphatec Holdings, Inc.
- Represented CarCor Investment Holdings LLC in an offering of 1,500,000 common shares of Cardiome Pharma Corp. owned by CarCor and 1,500,000 common shares from treasury of Cardiome, each at a price of Canadian $10.00 per common share, for a combined offering of Canadian $30 million. The offering was made on a bought deal basis pursuant to an underwriting agreement with Canaccord Genuity Corp. and Cormark Securities Inc. Cardiome is a Canadian specialty pharmaceutical company that commercializes cardiovascular therapies.
- Represented Reliance Life Sciences in a US$35 million investment in an MPM BioVentures Fund.
- Represented Intercell AG in connection with its acquisition of Cytos Biotechnology Ltd.’s platform technology for monoclonal antibody discovery.
- Represented Dr. George Jokhtaberidze in connection with various transactions and shareholder arrangements relating to his majority ownership interest in leading Georgian telecommunications company Magticom Ltd.
- Represented HealthpointCapital Partners as a selling shareholder in Alphatec Holdings, Inc.'s underwritten public offering of 18.4 million shares of common stock for total proceeds to HealthpointCapital and Alphatec of approximately US$85 million.
- Represented Encysive Pharmaceuticals Inc. in its acquisition by Pfizer Inc. for an equity value of approximately US$195 million.
- Represented International Specialty Products, Inc. on the sale of its UK-based hydrocolloids ingredients business to FMC Corporation.
- Represented Trinity Equity Investments I, LLC in its investment in, and recapitalization of, Ricerca Biosciences, LLC, which was completed in connection with Ricerca’s acquisition of the Discovery and Preclinical business of MDS Pharma Services.
- Represented Scient'x S.A. in connection with a multi-jurisdictional secured loan by Oxford Finance Corporation, a life sciences venture lender, to Scient'x USA, Inc. secured by the stock and assets of Scient'x S.A. and subsidiaries in France, Italy, Australia and the United Kingdom.
- Represented Piper Jaffray Ltd., the sole financial advisor, sponsor, underwriter, and broker to Vernalis plc, the London main market listed development stage pharmaceutical company, in its placing and open offer raising £24 million.
- Represented Collins Stewart Europe Limited, as Nomad and broker, to the AIM IPO of HipCricket, Inc., a U.S.-based mobile marketing company, and the proposed AIM IPO of a U.S.-based semi-conductor company.
- Represented HealthpointCapital Partners in its €71 million acquisition by way of private purchase and public tender offer of Ideal Medical Products, S.A., a French company listed on Euronext Paris.
- Represented Northwest Biotherapeutics, Inc., an OTC Bulletin Board quoted U.S. biotechnology company, on its admission to AIM and £15 million placing, valuing the company at approximately £70 million on a fully-diluted basis.
- Represented a medical device company, Scientix, S.A., in connection with its proposed initial public offering in France on Euronext Paris and simultaneous Regulation S/144A offering in the United States.
- Represented the UK-based Dunlop Slazenger Group in its disposition of the Maxfli golf brand and related assets to Taylor Made Golf Company, Inc. and in its license to a U.S.-based private equity group of the "Slazenger" golf brand for North America.
- Represented Kerr-McGee Corporation in connection with its successful repurchase of US$4 billion of common stock through a modified "Dutch Auction" tender offer.
- Represented Charlesbank Capital Partners, LLC, in connection with the sale of American Tire Distributors, Inc.
- Represented Calpine Corporation in a variety of debt tender offers for nearly US$1 billion of outstanding secured and unsecured notes including Euro- and British pound-denominated Senior Notes listed on the Luxembourg Stock Exchange.
- Represented Calpine Corporation in a highly structured Regulation D/Regulation S private placement of US$360,000,000 of redeemable preferred shares in a Jersey, Channel Islands subsidiary of Calpine.
- Represented U.S. individuals in the development and structuring of a proposed US$100 million private equity fund with a focus on investments in distressed middle-market companies and represented a Russian company in the development and structuring of a proposed US$100 million private equity fund with a focus on investments in the Russian oil and gas and mining industries.
News and client work
Contact details
- Clifford Chance, New York
- +1 212 878 3326
- Email me
- Follow me on LinkedIn
- Speaks English & German
- Practice area M&A corporate
Career and qualifications
- Georgetown University, School of Foreign Service (BS, European History & Diplomacy) 1993
- Georgetown University Law Center (JD), 1998
- Admitted as Attorney-at-Law in New York, 1999
- Joined Clifford Chance as Partner 2025
Awards and citations
- Chambers Global, Corporate/M&A (UK) and Corporate/M&A (US) (2012-2013)
- PLC Which Lawyer?, Capital Markets: Foreign Law Advice (2008-2011)
- Legal Experts, Corporate, M&A (2010)
- Legal 500 UK, Equity Capital Markets (2013)
- Legal 500 UK, M&A - Upper Mid-Market & Premium Deals (2013)
- Legal 500 UK, Flotations, Small and Mid-Cap (2011-2012)
- Legal 500 UK, M&A US Law Capability (2008-2011)